<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUPRANE - desflurane liquid </strong><br>General Injectables &amp; Vaccines, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).<br>Suprane (desflurane, USP) Volatile Liquid for Inhalation<br>Initial U.S. Approval:  1992</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Suprane (desflurane, USP) is an inhalation agent indicated:  (<a href="#section-1">1</a>)</p>
<ul>
<li>for induction and/or maintenance of anesthesia in adults (1.1)</li>
<li>for maintenance of anesthesia in pediatric patients following induction with agents other than Suprane (desflurane, USP) and intubation. Suprane (desflurane, USP) is not recommended for induction of anesthesia in pediatric patients. (1.2)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Suprane (desflurane, USP) should be administered only by persons trained in the administration of general anesthesia. It should only be administered using a vaporizer specifically designed and designated for use with Suprane (desflurane, USP). (2)</li>
<li>The administration of general anesthesia must be individualized based on the patient's response, including cardiovascular and pulmonary changes. (2)</li>
<li>Suprane (desflurane, USP) should not be used as the sole agent for anesthetic induction in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or where increases in heart rate or blood pressure are undesirable. (2.6)</li>
<li>Patients with intracranial space occupying lesions (2.7)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Volatile liquid for inhalation, 100% Suprane (desflurane, USP) (3)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Patients with known or suspected genetic susceptibility to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> (4)</li>
<li>Patients in whom general anesthesia is contraindicated (4)</li>
<li>Patients with known sensitivity to halogenated agent (4, 5.5)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant hyperthermia</span> may occur. (5.1)</li>
<li>Perioperative <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may occur. Patients with latent or overt neuromuscular disease, particularly with <span class="product-label-link" type="condition" conceptid="4296473" conceptname="Duchenne muscular dystrophy">Duchenne muscular dystrophy</span>, appear to be most vulnerable. (5.2)</li>
<li>Suprane (desflurane, USP) may cause sensitivity <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> in patients sensitized by previous exposure to halogenated anesthetics. (4, 5.5)</li>
<li>Suprane (desflurane, USP) is not recommended as an induction agent in children or for maintenance of anesthesia in non-intubated children due to a high incidence of moderate to severe respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions. (5.3, 8.4)</li>
<li>Suprane (desflurane, USP) can react with desiccated CO2 absorbents to produce <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span>. (5.4)</li>
<li>There are no adequate or well-controlled studies in pregnant or lactating women or during labor and delivery. Suprane (desflurane, USP) is a uterine relaxant. (8.1, 8.2, 8.3)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence&gt; 10%) are <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4233530" conceptname="Interrupted breathing">breath holding</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (6) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-800-262-3784 or FDA at 1-800-FDA-1088 or <span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Concomitant use of N2O, benzodiazepines and/or opioids reduces the MAC of Suprane (desflurane, USP). Adjust dose accordingly. (7.1, 7.3)</li>
<li>Suprane (desflurane, USP) decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. (7.2)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul>
<li>Pediatric:  Suprane (desflurane, USP) is not recommended as an induction agent in children or for maintenance of anesthesia in non-intubated children due to an increased incidence of moderate to severe respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions. (5.3, 8.4)</li>
<li>Geriatric:  The minimum alveolar concentration (MAC) of Suprane (desflurane, USP) decreases with increasing patient age. (8.5)</li>
</ul>
<p class="Highlighta"><span class="Bold">See 17 for PATIENT COUNSELING INFORMATION.</span>  (<a href="#section-8">8</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 6/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Induction of Anesthesia in Adults</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Maintenance of Anesthesia</a></h2>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Preanesthetic Medication</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Induction</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Maintenance</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Maintenance of Anesthesia in Intubated Pediatric Patients</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Recovery</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Neurosurgical Use</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Perioperative <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Respiratory Adverse Reactions in Pediatric Patients</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Interactions with Desiccated <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon Dioxide</span> Absorbents</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatobiliary Disorders</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Laboratory Findings</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Benzodiazepines and Opioids (MAC Reduction)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Neuromuscular Blocking Agents</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Concomitant Use with N2O</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Ambulatory Surgery</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Cardiovascular Surgery</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Geriatric Surgery</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Neurosurgery</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Pediatric Surgery</a></h2>
<h2><a href="#section-14.1" class="toc">16.1 Safety and Handling</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="L3e22df96-c207-4e68-9c90-919a5cbb94b9"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="L9a2727d6-74b8-4a82-8411-ddcef13440ed"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Induction of Anesthesia in Adults</h2>
<p class="First">SUPRANE (desflurane, USP) is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults.</p>
<p>SUPRANE (desflurane, USP) is not recommended for induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events <span class="Italics">[see Warnings and Precautions (5.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L6c773c73-cd08-4ed3-b329-9c89154edcb7"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Maintenance of Anesthesia</h2>
<p class="First">SUPRANE (desflurane, USP) is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. </p>
<p>After induction of anesthesia with agents other than SUPRANE (desflurane, USP), and tracheal intubation, SUPRANE (desflurane, USP) is indicated for maintenance of anesthesia in infants and children. SUPRANE (desflurane, USP) is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and secretions <span><span class="Italics">﻿[see Warnings and Precautions (5.3) and Clinical Studies (14.5)].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="L9eb5d7d4-e129-4450-bde1-7ea4572cb23e"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<p class="First">Only persons trained in the administration of general anesthesia should administer SUPRANE (desflurane, USP). Only a vaporizer specifically designed and designated for use with desflurane should be utilized for its administration. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available.</p>
<p>SUPRANE (desflurane, USP) is administered by inhalation. The administration of general anesthesia must be individualized based on the patient's response. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> increase as anesthesia with desflurane is deepened. The minimum alveolar concentration (MAC) of SUPRANE (desflurane, USP) decreases with increasing patient age. The MAC for SUPRANE (desflurane, USP) is also reduced by concomitant N2O administration <span><span class="Italics">﻿(see Table 1). </span><span>﻿The dose should be adjusted accordingly. The following table provides mean relative potency based upon age and effect of N2O in predominately ASA physical status I or II patients.</span></span></p>
<p><span><span>Benzodiazepines and opioids decrease the MAC of SUPRANE (desflurane, USP) <span><span class="Italics">﻿[see Drug Interactions (7.1, Table 3)]. </span><span>﻿SUPRANE (desflurane, USP) also decreases the doses of neuromuscular blocking agents required <span><span class="Italics">﻿[see Drug Interactions (7.2, Table 4)]. </span><span>﻿The dose should be adjusted accordingly.</span></span></span></span></span></span></p>
<p><img alt="Table1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Table1.jpg"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Le4568ba2-3a4c-4705-a1c7-e238f5a58fd2"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Preanesthetic Medication</h2>
<p class="First">Issues such as whether or not to premedicate and the choice of premedication(s) must be individualized. In clinical studies, patients scheduled to be anesthetized with desflurane frequently received IV preanesthetic medication, such as opioid and/or benzodiazepine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L40772dc0-5b14-4ae3-83ad-6f2a9e2d2511"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Induction</h2>
<p class="First">In adults, some premedicated with opioid, a frequent starting concentration was 3% desflurane, increased in 0.5-1.0% increments every 2 to 3 breaths. End-tidal concentrations of 4-11%, desflurane with and without N2O, produced anesthesia within 2 to 4 minutes. When desflurane was tested as the primary anesthetic induction agent, the incidence of upper airway irritation (<span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, breathholding, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and secretions) was high. During induction in adults, the overall incidence of oxyhemoglobin desaturation (SpO2 &lt; 90%) was 6% <span class="Italics">﻿[see Adverse Reactions (6.1)].</span></p>
<p>﻿After induction in adults with an intravenous drug such as thiopental or propofol, desflurane can be started at approximately 0.5-1 MAC, whether the carrier gas is O2 or N2O/O2.</p>
<p>Inspired concentrations of SUPRANE (desflurane, USP) greater than 12% have been safely administered to patients, particularly during induction of anesthesia. Such concentrations will proportionately dilute the concentration of oxygen; therefore, maintenance of an adequate concentration of oxygen may require a reduction of nitrous oxide or air if these gases are used concurrently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Le92c03a2-7fce-4186-b1a5-bdd4cc4ac8c0"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Maintenance</h2>
<p class="First">Surgical levels of anesthesia in adults may be maintained with concentrations of 2.5-8.5% SUPRANE (desflurane, USP) with or without the concomitant use of nitrous oxide. In children, surgical levels of anesthesia may be maintained with concentrations of 5.2-10% SUPRANE (desflurane, USP) with or without the concomitant use of nitrous oxide. </p>
<p>During the maintenance of anesthesia with inflow rates of 2 L/min or more, the alveolar concentration of desflurane will usually be within 10% of the inspired concentration <span><span class="Italics">﻿[Fa/FI, see Figure 2 in Clinical Pharmacology (12.3)].</span></span></p>
<p><span><span class="Italics"></span><span>﻿During the maintenance of anesthesia, increasing concentrations of SUPRANE (desflurane, USP) produce dose-dependent decreases in blood pressure. Excessive decreases in blood pressure may be due to depth of anesthesia and in such instances may be corrected by decreasing the inspired concentration of SUPRANE (desflurane, USP). </span></span></p>
<p><span><span>Concentrations of desflurane exceeding 1 MAC may increase heart rate. Thus with this drug, an increased heart rate may not serve reliably as a sign of inadequate anesthesia.</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L39891c9f-6fa8-4c74-af27-328eb4aac24a"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Maintenance of Anesthesia in Intubated Pediatric Patients</h2>
<p class="First">SUPRANE (desflurane, USP) is approved for maintenance of anesthesia in infants and children after induction of anesthesia with agents other than desflurane, and tracheal intubation.</p>
<p>SUPRANE (desflurane, USP), with or without N2O, and halothane, with or without N2O were studied in three clinical trials of pediatric patients aged 2 weeks to 12 years (median 2 years) and ASA physical status I or II. The concentration of SUPRANE (desflurane, USP) required for maintenance of general anethesia is age-dependent <span><span class="Italics">﻿[see Clinical Studies (14.5)].</span></span></p>
<p><span><span class="Italics"></span><span>﻿Changes in blood pressure during maintenance of and recovery from anesthesia with desflurane/N2O/O2 are similar to those observed with halothane/N2O/O2. Heart rate during maintenance of anesthesia is approximately 10 beats per minute faster with desflurane than with halothane. Patients were judged fit for discharge from post-anesthesia care units within one hour with both desflurane and halothane. There were no differences in the incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> between patients receiving desflurane or halothane.</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L9d67b710-cf23-467f-be20-25926f293754"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Recovery</h2>
<p class="First">The recovery from general anethesia should be assessed carefully before patients are discharged from the post anesthesia care unit (PACU).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L63f9dd60-653f-4e85-94e1-999f8228833b"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, maintenance of normal hemodynamics is important to prevent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>. Desflurane should not be used as the sole agent for anesthetic induction in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or patients where increases in heart rate or blood pressure are undesirable. It should be used with other medications, preferably intravenous opioids and hypnotics <span><span class="Italics">﻿[see Clinical Studies (14.2)].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L99ba63e6-0be4-4adf-8b7a-d0a7e643c7d9"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Neurosurgical Use</h2>
<p class="First">SUPRANE (desflurane, USP) may produce a dose-dependent increase in cerebrospinal fluid pressure (CSFP) when administered to patients with intracranial space occupying lesions. Desflurane should be administered at 0.8 MAC or less, and in conjunction with a barbiturate induction and <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> (hypocapnia) until cerebral decompression in patients with known or suspected increases in CSFP. Appropriate attention must be paid to maintain cerebral perfusion pressure <span><span class="Italics">﻿[see Clinical Studies (14.4)].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="L5e3c724b-240b-4974-8d0e-a5527913636e"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Colorless, non-flammable, volatile liquid (below 22.8°C) for inhalation, 100% SUPRANE (desflurane, USP)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="L78117529-2a92-47b1-a6f0-ea6b7b393768"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<p class="First">The use of SUPRANE (desflurane, USP) is contraindicated in the following conditions:</p>
<ul>
<li>Known or suspected genetic susceptibility to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.</li>
<li>Patients in whom general anesthesia is contraindicated.</li>
<li>Patients with known sensitivity to SUPRANE (desflurane, USP) or to other halogenated agents <span class="Italics">[see Warnings and Precautions (5.5)].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="L3d684b0b-218d-4f7e-9aad-81e9bbe82b6e"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="L3d5b8275-b1ff-43aa-ba29-0187f82708a9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span></h2>
<p class="First">In susceptible individuals, potent inhalation anesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. In genetically susceptible pigs, desflurane induced <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. The clinical syndrome is signaled by <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, and may include <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and/or unstable blood pressure. Some of these nonspecific signs may also appear during <span class="product-label-link" type="condition" conceptid="4086497" conceptname="Light anesthesia">light anesthesia</span>:  acute <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>.</p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> includes discontinuation of triggering agents, administration of intravenous dantrolene sodium, and application of supportive therapy. (Consult prescribing information for dantrolene sodium intravenous for additional information on patient management.) <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> may appear later, and urine flow should be monitored and sustained if possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lffc3bc40-b8f8-4456-bc5a-3e6d1cba4c83"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Perioperative <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly <span class="product-label-link" type="condition" conceptid="4296473" conceptname="Duchenne muscular dystrophy">Duchenne muscular dystrophy</span>, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatinine kinase levels and, in some cases, changes in urine consistent with <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>. Despite the similarity in presentation to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, none of these patients exhibited signs or symptoms of <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> or hypermetabolic state. Early and aggressive intervention to treat the <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and resistant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> is recommended, as is subsequent evaluation for latent neuromuscular disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L02baebe4-f1da-48fd-a176-49290a73f456"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Respiratory Adverse Reactions in Pediatric Patients</h2>
<p class="First">SUPRANE (desflurane, USP) is not recommended for induction of general anesthesia via mask in children due to a high incidence of moderate to severe respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, breathholding, and secretion seen in clinical studies <span><span class="Italics">﻿[see Clinical Studies (14.5)].</span></span></p>
<p><span><span class="Italics"></span><span>﻿SUPRANE (desflurane, USP) is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions <span><span class="Italics">﻿[see Clinical Studies (14.5)]. </span><span>﻿Caution should be exercised when SUPRANE (desflurane, USP) is used for maintenance anesthesia with laryngeal mask airway (LMA) in children 6 years old or younger because of the increased potential for adverse respiratory events, e.g. <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, especially with removal of the LMA under deep anesthesia <span><span class="Italics">﻿[see Pediatric Use (8.4)].</span></span></span></span></span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L2e4c7306-e35e-4fd2-91ec-b658356333f5"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Interactions with Desiccated <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon Dioxide</span> Absorbents</h2>
<p class="First">Desflurane like some other inhalation anesthetics, can react with desiccated <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> (CO2) absorbents to produce <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span> that may result in elevated levels of <span class="product-label-link" type="condition" conceptid="4269049" conceptname="Carboxyhemoglobin">carboxyhemoglobin</span> in some patients. Case reports suggest that barium hydroxide lime and soda lime become desiccated when fresh gases are passed through the CO2 canister at high flow rates over many hours or days. When a clinician suspects that CO2 absorbent may be desiccated, it should be replaced before the administration of SUPRANE (desflurane, USP).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L56410462-52cc-4cb0-9e28-6089c69a5752"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatobiliary Disorders</h2>
<p class="First">With the use of halogenated anesthetics, disruption of hepatic function, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">icterus</span> and fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> have been reported; such reactions appear to indicate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. As with other halogenated anesthetic agents. SUPRANE (desflurane, USP) may cause sensitivity <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> in patients who have been sensitized by previous exposure to halogenated anesthetics <span><span class="Italics">﻿[see Contraindications (4)]. </span><span>﻿Cirrhosis, <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span> or other pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> may be a reason to select an anesthetic other than a halogenated anesthetic. As with all halogenated anesthetics, repeated anesthesia within a short period of time should be approached with caution.</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L1c022de9-3917-4d8c-bcc1-ad5c4f5f004b"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Laboratory Findings</h2>
<p class="First">Transient elevations in glucose and white blood cell count may occur as with use of other anesthetic agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Lfd9c4dd4-a4b2-47e0-b14a-7cb8460cd0c1"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="L32376e30-9e9a-4a62-8102-f7a4abf86a5a"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Adverse event information is derived from controlled clinical trials, the majority of which were conducted in the United States. The studies were conducted using a variety of premedications, other anesthetics, and surgical procedures of varying length. Most adverse events reported were mild and transient, and may reflect the surgical procedures, patient characteristics (including disease) and/or medications administered.</p>
<p>Of the 2,143 patients exposed to SUPRANE (desflurane, USP) in clinical trials, 370 adults and 152 children were induced with desflurane alone and 987 patients were maintained principally with desflurane. The frequencies given reflect the percent of patients with the event. Each patient was counted once for each type of adverse event. They are presented in alphabetical order according to body system.</p>
<p><img alt="Table2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Table2.jpg"></p>
<p><img alt="Image1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image1.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L7d9c3ce6-c88f-4d48-9a85-0a0cb5c076ba"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post Marketing Experience</h2>
<p class="First"><span class="Italics">﻿The following adverse reactions have been identified during post-approval use of SUPRANE (desflurane, USP). Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</span></p>
<p><span class="Italics">Blood and Lymphatic System Disorders:  </span>﻿<span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders:  </span>﻿<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:  </span>﻿<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:  </span>﻿<span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">Ocular icterus</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:  </span>﻿<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de pointes</span>, ventricular failure, ventricular <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:  </span>﻿<span class="product-label-link" type="condition" conceptid="4289933" conceptname="Malignant hypertension">Malignant hypertension</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:  </span>﻿<span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:  </span>﻿<span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Pancreatitis acute</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Italics">Hepatobiliary Disorders:  </span>﻿<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">cytolytic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorder</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorder:  </span>﻿<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></p>
<p><span class="Italics">Musculoskeletal, Connective Tissue and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span>:  </span>﻿<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions:  </span>﻿<span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Hyperthermia malignant</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="Italics">Investigations:  </span>﻿Electrocardiogram ST-T change, electrocardiogram T-wave inversion, tranaminases increased, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, coagulation test abnormal, <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> increased</p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications*:  </span>﻿<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachyarrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> <span class="product-label-link" type="condition" conceptid="434231" conceptname="Burn confined to eye and adnexa">eye burns</span>, <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">blindness transient</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, accidental exposure, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">skin burning sensation</span>, <span class="product-label-link" type="condition" conceptid="4168611" conceptname="Effect of drug maladministration">drug administration error</span></p>
<p>*All of reactions categorized within this SOC were accidental exposures to non-patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="L30cd38ae-ecf7-4cc9-a40d-70ae301fe073"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<p class="First">No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials. The effect of desflurane on the disposition of other drugs has not been determined. Similar to isoflurane, desflurane does not predispose to premature <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> in the presence of exogenously infused epinephrine in swine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="L6c359a02-302b-4c15-8fad-04ff0c107628"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Benzodiazepines and Opioids (MAC Reduction)</h2>
<p class="First">Benzodiazepines and opioids decrease the amount of desflurane (MAC) needed to produce anesthesia. This effect is shown in Table 3 for intravenous midazolam (25-50 ug/kg) and intravenous fentanyl (3-6 ug/kg) in patients of two different age groups.</p>
<p><img alt="Table3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Table3.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L6f241ced-abec-4ef3-a5cb-5fcdae6a36c6"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Neuromuscular Blocking Agents</h2>
<p class="First">Anesthetic concentrations of desflurane at equilibrium (administered for 15 or more minutes before testing) reduced the ED95 of succinylcholine by approximately 30% and that of atracurium and pancuronium by approximately 50% compared to N2O/opioid anesthesia <span class="Italics">﻿(see Table 4). </span>﻿The effect of desflurane on duration of nondepolarizing <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> has not been studied.</p>
<p><img alt="Table4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Table4.jpg"></p>
<p>Dosage reduction of neuromuscular blocking agents during induction of anesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span>, because potentiation of neuromuscular blocking agents requires equilibration of muscle with the delivered partial pressure of desflurane.</p>
<p>Among nondepolarizing drugs, pancuronium, atracurium, and vecuronium interactions have been studied. In the absence of specific guidelines:</p>
<ol>
<li>For endotracheal intubation, do not reduce the dose of nondepolarizing muscle relaxants or succinylcholine.</li>
<li>During maintenance of anesthesia, the dose of nondepolarizing muscle relaxants is likely to be reduced compared to that during N2O/opioid anesthesia. Administration of supplemental doses of muscle relaxants should be guided by the response to nerve stimulation.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="La1dee090-4b2a-4d6a-a5d4-9c10f5fe5292"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Concomitant Use with N2O</h2>
<p class="First">Concomitant administration of N2O reduces the MAC of SUPRANE (desflurane, USP) <span><span class="Italics">﻿[see Dosage and Administration (2), Table 1].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="L434af53c-75d9-43cd-80af-2e0828fcbb72"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="La9caa867-1809-4d4d-890b-636d22a3ba07"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Reproduction studies have been performed in rats at doses up to at 1 MAC hour for a minimum of 21 days and have revealed no evidence of impaired fertility or harm to the fetus due to SUPRANE (desflurane, USP).</p>
<p>No teratogenic effect was observed at approximately 10 and 13 cumulative MAC-Hour exposures at 1 MAC-Hour per day during organogenesis in rats or rabbits. At higher doses increased incidences of post-implantation loss and maternal toxicity were observed. However, at 10 MAC-Hours cumulative exposure in rats, about 6% decrease in the weight of male pups was observed at preterm caesarean delivery.</p>
<p>Rats exposed to SUPRANE (desflurane, USP) at 1 MAC-Hour per day from gestation day 15 to lactation day 21, did not show signs of dystocia. Body weights of pups delivered by these dams at birth and during lactation were comparable to that of control pups. No treatment related behavioral changes were reported in these pups during lactation.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="L1cd3c8a6-da51-4ac3-9c18-f11b85ceb404"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The safety of desflurane during labor or delivery has not been demonstrated. SUPRANE (desflurane, USP) is a uterine-relaxant.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="L01d4dfec-3df8-4140-8c1c-7acbc7267096"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SUPRANE (desflurane, USP) is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Lcbc9c044-31c3-4bb1-ac81-bd7b74fd3893"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><span><span class="Underline"><span class="Italics">﻿Respiratory Adverse Reactions in Pediatric Patients</span></span></span></p>
<p><span><span class="Underline"><span class="Italics"></span></span><span>﻿SUPRANE (desflurane, USP) is approved for maintenance of anesthesia in infants and children after induction of anesthesia with agents other than SUPRANE (desflurane, USP), and tracheal intubation.</span></span></p>
<p><span><span>SUPRANE (desflurane, USP) is not recommended for induction of general anesthesia via mask in children because of the high incidence of moderate to severe respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> (50%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> (72%), breathholding (68%), increase in secretions (21%) and oxyhemoglobin desaturation (SpO2 &lt; 90%) (26%) seen in clinical studies <span><span class="Italics">﻿[see Clinical Studies (14.5)].</span></span></span></span></p>
<p><span><span><span><span class="Italics"></span><span>﻿SUPRANE (desflurane, USP) is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions <span><span class="Italics">﻿[see Clinical Studies (14.5)]. </span><span>﻿Caution should be exercised when SUPRANE (desflurane, USP) is used for maintenance with laryngeal mask airway (LMA) in children 6 years old or younger because of the increased potential for adverse respiratory events, e.g. <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, especially with removal of the LMA under deep anesthesia <span><span class="Italics">﻿[see Warnings and Precautions (5.3)].</span></span></span></span></span></span></span></span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="L3608bac9-ddef-4485-a389-8706a39eb293"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The minimum alveolar concentration (MAC) of SUPRANE (desflurane, USP) decreases with increasing patient age. The dose should be adjusted accordingly. The average MAC for SUPRANE (desflurane, USP) in a 70 year old patient is two-thirds the MAC for a 20 year old patient <span><span class="Italics">﻿[see Dosage and Administration (2) Table 1 and Clinical Studies (14.3)]. </span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L13472830-dfaa-487b-8140-58c28d3b2e87"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Concentrations of 1-4% SUPRANE (desflurane, USP) in nitrous oxide/oxygen have been used in patients with chronic renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and during renal transplantation surgery. Because of minimal metabolism, a need for dose adjustment in patients with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is not to be expected.</p>
<p>Nine patients receiving desflurane (N=9) were compared to 9 patients receiving isoflurane, all with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span> (serum creatinine 1.5-6.9 mg/dL). No differences in hematological or biochemical tests, including renal function evaluation, were seen between the two groups. Similarly, no differences were found in a comparison of patients receiving either desflurane (N=28) or isoflurane (N=30) undergoing renal transplant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L1e06a13e-c09c-461f-af72-334d553a8a2a"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Eight patients receiving SUPRANE (desflurane, USP) were compared to six patients receiving isoflurane, all with chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> (<span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4340383" conceptname="Alcoholic hepatitis">alcoholic hepatitis</span>, or cirrhosis). No differences in hematological or biochemical tests, including enzymes and hepatic function evaluation, were seen. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="L20d3b169-b682-4f58-87b0-f36376caefcc"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First">The symptoms of overdosage of SUPRANE (desflurane, USP) can present as a deepening of anesthesia, cardiac and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in spontaneously breathing patients, and cardiac <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in ventilated patients in whom <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span> and <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> may occur only at a late stage. In the event of overdosage, or suspected overdosage, take the following actions:  discontinue administration of SUPRANE (desflurane, USP), maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Lef58980e-57fd-4bfc-9627-737334056fd6"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">SUPRANE (desflurane, USP), a nonflammable liquid administered via vaporizer, is a general inhalation anesthetic. It is (±)1,2,2,2-tetrafluoroethyl difluoromethyl ether:</p>
<p><img alt="Formula1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Formula1.jpg"></p>
<p><img alt="Image2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image2.jpg"></p>
<p>Desflurane is nonflammable as defined by the requirements of International Electrotechnical Commission 601-2-13.</p>
<p>Desflurane is a colorless, volatile liquid below 22.8°C. Data indicate that desflurane is stable when stored under normal room lighting conditions according to instructions.</p>
<p>Desflurane is chemically stable. The only known degradation reaction is through prolonged direct contact with soda lime producing low levels of fluoroform (CHF3). The amount of CHF3 obtained is similar to that produced with MAC-equivalent doses of isoflurane. No discernible degradation occurs in the presence of strong acids.</p>
<p>Desflurane does not corrode stainless steel, brass, aluminum, anodized aluminum , nickel plated brass, copper, or beryllium.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Le0222b7c-8361-4aaf-a9c9-290750d16801"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="Ld50a68b6-e783-4964-a67b-501fd798527b"></a><a name="section-11.1"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Changes in the clinical effects of SUPRANE (desflurane, USP) rapidly follow changes in the inspired concentration. The duration of anesthesia and selected recovery measures for SUPRANE (desflurane, USP) are given in the following tables:</p>
<p>In 178 female outpatients undergoing laparoscopy, premedicated with fentanyl (1.5-2.0 ug/kg), anesthesia was initiated with propofol 2.5 mg/kg, desflurane/N2O 60% in O2 or desflurane/O2 alone. Anesthesia was maintained with either propofol 1.5-9.0 mg/kg/hr, desflurane 2.6-8.4% in N2O 60% in O2, or desflurane 3.1-8.9% in O2.</p>
<p><img alt="Image3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image3.jpg"></p>
<p>In 88 unpremedicated outpatients, anesthesia was initiated with thiopental 3-9 mg/kg or desflurane in O2. Anesthesia was maintained with isoflurane 0.7-1.4% in N2O 60%, desflurane 1.8-7.7% in N2O 60%, or desflurane 4.4-11.9% in O2.</p>
<p><img alt="Image4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image4.jpg"></p>
<p>Recovery from anesthesia was assessed at 30, 60, and 90 minutes following 0.5 MAC desflurane (3%) or isoflurane (0.6%) in N2O 60% using subjective and objective tests. At 30 minutes after anesthesia, only 43% of the isoflurane group were able to perform the psychometric tests compared to 76% in the desflurane group (p &lt; 0.05).</p>
<p><img alt="Image5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image5.jpg"></p>
<p>SUPRANE (desflurane, USP) was studied in twelve volunteers receiving no other drugs. Hemodynamic effects during controlled ventilation (PaCO2 38 mm Hg) were:</p>
<p><img alt="Image6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image6.jpg"></p>
<p>When the same volunteers breathed spontaneously during desflurane anesthesia, systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and mean arterial <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span>; <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span>, heart rate, <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, and central venous pressure (CVP) increased compared to values when the volunteers were conscious. <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">Cardiac index</span>, <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, and CVP were greater during spontaneous ventilation than during controlled ventilation.</p>
<p>During spontaneous ventilation in the same volunteers, increasing the concentration of SUPRANE (desflurane, USP) from 3% to 12% decreased tidal volume and increased arterial <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> and <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>. The combination of N2O 60% with a given concentration of desflurane gave results similar to those with desflurane alone. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> produced by desflurane is similar to that produced by other potent inhalation agents.</p>
<p>The use of desflurane concentrations higher than 1.5 MAC may produce <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
<p><img alt="Figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Figure1.jpg"></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="L341bae0c-fd99-4b4f-86c9-97787488698b"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Due to the volatile nature of desflurane in plasma samples, the washin-washout profile of desflurane was used as a surrogate of plasma pharmacokinetics. SUPRANE (desflurane, USP) is a volatile liquid inhalation anesthetic minimally biotransformed in the liver in humans. Less than 0.02% of the desflurane absorbed can be recovered as urinary metabolites (compared to 0.2% for isoflurane). Eight healthy male volunteers first breathed 70% N2O/30% O2 for 30 minutes and then a mixture of desflurane 2.0%, isoflurane 0.4%, and halothane 0.2% for another 30 minutes. During this time, inspired and end-tidal concentrations (FI and FA) were measured. The FA/FI (washin) value at 30 minutes for desflurane was 0.91, compared to 1.00 for N2O, 0.74 for isoflurane, and 0.58 for halothane <span class="Italics">(see Figure 2). </span>The washin rates for halothane and isoflurane were similar to literature values. The washin was faster for desflurane than for isoflurane and halothane at all time points. The FA/FAO (washout) value at 5 minutes was 0.12 for desflurane, 0.22 for isoflurane, and 0.25 for halothane <span class="Italics">(see Figure 3). </span>The washout for desflurane was more rapid than that of isoflurane and halothane at all elimination time points. By 5 days, the FA/FAO for desflurane is 1/20th of that for halothane or isoflurane.</p>
<p><img alt="Figure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Figure2.jpg"><img alt="Figure3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Figure3.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Lc8a1ef1f-7190-40ad-bcee-9633ff165d52"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="L0deb3894-b8d4-4b21-b1d6-5c5568c07c03"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal carcinogenicity studies have not been performed with SUPRANE (desflurane, USP). <span class="Italics">﻿In vitro </span>﻿and <span class="Italics">﻿In vivo </span>﻿genotoxicity studies did not demonstrate mutagenicity or chromosomal damage by desflurane. Tests for genotoxicity included the Ames mutation assay, the metaphase analysis of human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and the mouse micronucleus assay. </p>
<p>Fertility was not affected after 1 MAC-Hour per day exposure (cumulative 63 and 14 MAC-Hours for males and females, respectively). At higher doses, parental toxicity (mortalities and reduced <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>) was observed which could affect fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Lbc084dfc-26ea-44c5-a28e-85775f33e6d1"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<p class="First">The efficacy of SUPRANE (desflurane, USP) was evaluated in 1,843 patients including ambulatory (N=1,061), cardiovascular (N=277), geriatric (N=103), neurosurgical (N=40), and pediatric (N=235) patients. Clinical experience with these patients and with 1,087 control patients in these studies not receiving desflurane is described below. Althrough desflurane can be used in adults for the inhalation induction of anesthesia via mask, it produces a high incidence of respiratory irritation (<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, breathholding, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, increased secretions, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>). Oxyhemoglobin saturation below 90% occurred in 6% of patients (from pooled data, N = 370 adults).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb02b975a-a00b-4e87-9fc2-7e95963cb243"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Ambulatory Surgery</h2>
<p class="First">SUPRANE (desflurane, USP) plus N2O was compared to isoflurane plus N2O in multicenter studies (21 sites) of 792 ASA physical status I, II, or III patients aged 18-76 years (median 32). </p>
<p><span class="Underline"><span class="Italics">Induction</span></span></p>
<p><span><span class="Underline"><span class="Italics"></span></span>Anesthetic induction begun with thiopental and continued with desflurane was associated with a 7% incidence of oxyhemoglobin saturation of 90% or less (from pooled data, N = 307) compared with 5% in patients in whom anesthesia was induced with thiopental and isoflurane (from pooled data, N = 152).</span></p>
<p><span class="Underline"><span class="Italics"><span>Maintenance &amp; Recovery</span></span></span></p>
<p><span class="Underline"><span class="Italics"><span><span></span></span></span></span><span><span>SUPRANE (desflurane, USP) with or without N2O or other anesthetics was generally well tolerated. There were no differences between desflurane and the other anesthetics studied in the times that patients were judged fit for discharge. </span></span></p>
<p><span><span>In one outpatient study, patients received a standardized anesthetic consisting of thiopental 4.2-4.4 mg/kg, fentanyl 3.5-4.0 ug/kg, vecuronium 0.05-0.07 mg/kg, and N2O 60% in oxygen with either desflurane 3% or isoflurane 0.6%. Emergence times were significantly different; but times to sit up and discharge were not different <span class="Italics">(see Table 5).</span></span></span></p>
<p><img alt="Table5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Table5.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ld42caf53-c49b-45b0-a86a-548a69c415e2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Cardiovascular Surgery</h2>
<p class="First">Desflurane was compared to isoflurane, sufentanil or fentanyl for the anesthetic management of coronary artery bypass graft (CABG), <span class="product-label-link" type="condition" conceptid="198177" conceptname="Abdominal aortic aneurysm">abdominal aortic aneurysm</span>, peripheral vascular and carotid endarterectomy surgery in 7 studies at 15 centers involving a total of 558 patients. In all patients except the desflurane vs. sufentanil study, the volatile anesthetics were supplemented with intravenous opioids, usually fentanyl. Blood pressure and heart rate were controlled by changes in concentration of the volatile anesthetics or opioids and cardiovascular drugs if necessary. Oxygen (100%) was the carrier gas in 253 of 277 desflurane cases (24 of 277 received N2O/O2).</p>
<p><img alt="Image7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image7.jpg"></p>
<p>No differences were found in cardiovascular outcome (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>) among desflurane and the other anesthetics.</p>
<p><span class="Underline"><span class="Italics">﻿Induction</span></span></p>
<p>﻿Desflurane should not be used as the sole agent for anesthetic induction in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or any patients where increases in heart rate or blood pressure are undesirable. In the desflurane vs. sufentanil study, anesthetic induction with desflurane without opioids was associated with new transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> in 14 patients vs. 0 in the sufentanil group. In the desflurane group, mean heart rate, arterial pressure, and pulmonary <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span> and <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> decreased in contrast to no change in the sufentanil group. Cardiovascular drugs were used frequently in both groups:  especially esmolol in the desflurane group (56% vs. 0%) and phenylephrine in the sufentanil group (43% vs. 27%). When 10 ug/kg of fentanyl was used to supplement induction of anesthesia at one other center, continuous 2-lead ECG analysis showed a low incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and no difference between desflurane and isoflurane. If desflurane is to be used in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, it should be used in conjunction with other medications for induction of anesthesia, preferably intravenous opioids and hypnotics.</p>
<p><span class="Underline"><span class="Italics">﻿Maintenance &amp; Recovery</span></span></p>
<p>﻿In studies where desflurane or isoflurane anesthesia was supplemented with fentanyl, there were no differences in hemodynamic variables or the incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> in the patients anesthetized with desflurane compared to those anesthetized with isoflurane.</p>
<p>During the precardiopulmonary bypass period, in the desflurane vs. sufentanil study where the desflurane patients received no intravenous opioid, more desflurane patients required cardiovascular adjuvants to control hemodynamics than the sufentanil patients. During this period, the incidence of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> detected by ECG or echocardiography was not statistically different between desflurane (18 of 99) and sufentanil (9 of 98) groups. However, the duration and severity of the ECG-detected <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> was significantly less in the desflurane group. The incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> after cardiopulmonary bypass and in the ICU did not differ between groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lc75d469d-c650-4e57-8186-1b5ec52001ad"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Geriatric Surgery</h2>
<p class="First">SUPRANE (desflurane, USP) plus N2O was compared to isoflurane plus N2O in a multicenter study (6 sites) of 203 ASA physical status II or III elderly patients, aged 57-91 years (median 71).</p>
<p><span><span class="Underline"><span class="Italics">﻿Induction</span></span></span></p>
<p><span><span class="Underline"><span class="Italics"></span></span><span>﻿Most patients were premedicated with fentanyl (mean 2 ug/kg), preoxygenated, and received thiopental (mean 4.3 mg/kg IV) or thiamylal (mean 4 mg/kg IV) followed by succinylcholine (mean 1.4 mg/kg IV) for intubation.</span></span></p>
<p><span class="Underline"><span class="Italics"><span><span><span>﻿Maintenance &amp; Recovery</span></span></span></span></span></p>
<p><span class="Underline"><span class="Italics"><span><span><span></span></span></span></span></span><span><span><span><span>﻿Heart rate and arterial blood pressure remained within 20% of preinduction baseline values during administration of SUPRANE (desflurane, USP) 0.5-7.7% (average 3.6%) with 50-60% N2O. Induction, maintenance, and recovery cardiovascular measurements did not differ from those during isoflurane/N2O administration or did the postoperative incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> differ. The most common cardiovascular adverse event was <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurring in 8% of the desflurane patients and 6% of the isoflurane patients.</span></span></span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L5730bd77-1e93-4a26-a3ca-e1c632525869"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Neurosurgery</h2>
<p class="First">SUPRANE (desflurane, USP) was studied in 38 patients aged 26-76 years (median 48 years), ASA physical status II or III undergoing neurosurgical procedures for intracranial lesions.</p>
<p><span><span class="Underline"><span class="Italics">﻿Induction</span></span></span></p>
<p><span><span class="Underline"><span class="Italics"></span></span><span>﻿Induction consisted of standard neuroanesthetic techniques including <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> and thiopental.</span></span></p>
<p><span class="Underline"><span class="Italics"><span><span><span>﻿Maintenance</span></span></span></span></span></p>
<p><span class="Underline"><span class="Italics"><span><span><span></span></span></span></span></span><span><span><span><span>﻿No change in cerebrospinal fluid pressure (CSFP) was observed in 8 patients who had intracranial tumors when the dose of desflurane was 0.5 MAC in N2O 50%. In another study of 9 patients with intracranial tumors, 0.8 MAC desflurane/air/O2 did not increase CSFP above post induction baseline values. In a different study of 10 patients receiving 1.1 MAC desflurane/air/O2, CSFP increased 7 mm Hg (range 3-13 mm Hg increase, with final values of 11-26 mm Hg) above the pre-drug values.</span></span></span></span></p>
<p><span><span><span><span>All volatile anesthetics may increase intracranial pressure in patients with intracranial space occupying lesions. In such patients, desflurane should be administered at 0.8 MAC or less, and in conjunction with a barbiturate induction and <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> (hypocapnia) in the period before cranial decompression. Appropriate attention must be paid to maintain cerebral perfusion pressure. The use of a lower dose of desflurane and the administration of a barbiturate and mannitol would be predicted to lessen the effect of desflurane on CSFP.</span></span></span></span></p>
<p><span><span><span><span>Under hypocapnic conditions (PaCO2 27 mm Hg) desflurane 1 and 1.5 MAC did not increase cerebral blood flow (CBF) in 9 patients undergoing craniotomies. CBF reactivity to increasing PaCO2 from 27 to 35 mm Hg was also maintained at 1.25 MAC desflurane/air/O2.</span></span></span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb6b0ba59-7cc6-4a76-b29e-73f55d5c76f6"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Pediatric Surgery</h2>
<p class="First">In a clinical safety trial conducted in children aged 2 to 16 years (mean 7.4 years), following induction with another agent, SUPRANE (desflurane, USP) and isoflurane (in N2O/O2) were compared when delivered via face mask or laryngeal mask airway (LMA) for maintenance of anesthesia, after induction with intravenous propofol or inhaled sevoflurane, in order to assess the relative incidence of respiratory adverse events.</p>
<p><img alt="Image8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image8.jpg"></p>
<p>SUPRANE (desflurane, USP) was associated with higher rates (compared with isoflurane) of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and secretions with an overall rate of respiratory events of 39%. Of the pediatric patients exposed to desflurane, 5% experienced severe <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> (associated with significant desaturation; <span><span class="Italics">﻿i.e. </span><span>﻿SpO2 of &lt;90% for &gt;15 seconds, or requiring succinylcholine), across all ages, 2-16 years old. Individual age group incidences of severe <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> were 9% for 2-6 years old, 1% for 7-11 years old, and 1% for 12-16 years old. Removal of LMA under deep anesthesia (MAC range 0.6 - 2.3 with a mean of 1.12 MAC) was associated with a further increase in frequency of respiratory adverse events as compared to awake LMA removal or LMA removal under deep anesthesia with the comparator. The frequency and severity of non-respiratory adverse events were comparable between the two groups. </span></span></p>
<p><span><span>The incidence of respiratory events under these conditions was highest in children aged 2-6 years. Therefore, similar studies under the age of 2 years were not initiated.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="La9f41bf0-66ae-4724-9921-99bf2f7887ec"></a><a name="section-14"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">SUPRANE (desflurane, USP) is available in an amber-colored glass bottle or an aluminum bottle containing 240 mL of desflurane as follows:</p>
<p><img alt="Image9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Image9.jpg"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="L763f01e6-4cae-4dbc-9a30-d013518375de"></a><a name="section-14.1"></a><p></p>
<h2>16.1 Safety and Handling</h2>
<p class="First"><span class="Underline"><span class="Italics">﻿Occupational Caution</span></span></p>
<p>﻿There is no specific work exposure limit established for SUPRANE (desflurane, USP). However, the National Institute for Occupational Safety and Health Administration (NIOSH) recommends that no worker should be exposed at ceiling concentrations greater than 2 ppm of any halogenated anesthetic agent over a sampling period not to exceed one hour.</p>
<p>Principle routes of exposure include:</p>
<p>Skin contact - May cause <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>. In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Seek medical attention if irritation develops.</p>
<p>Eye contact - May cause <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>. In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Seek medical attention if irritation develops.</p>
<p>Ingestion - No specific hazards other than therapeutic effects. Do NOT induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> unless directed to do so by medical personnel. Never give anything by mouth to an <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> person. If large quantities of this material are swallowed, seek medical attention immediately.</p>
<p>Inhalation - If individual smell vapors, or experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, they should be moved to an area with fresh air. Individuals could also experience the following:</p>
<p>Cardiovascular effects:  may include fluctuations in heart rate, changes in blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. Respiratory effects:  may include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasms</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasms</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Gastrointestinal effects:  may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, loss of appetite. Nervous System effects:  may include <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, disturbance of speech, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p>The predicted effects of acute overexposure by inhalation of SUPRANE (desflurane, USP) include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or (in extreme cases) <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> <span class="Italics">﻿[see Overdosage (10)].</span></p>
<p>﻿There are no documented adverse effects of chronic exposure to halogenated anesthetic vapors (<span class="Underline">﻿W</span>﻿aste <span class="Underline">﻿A</span><span>﻿nesthetic <span><span class="Underline">﻿G</span><span>﻿ases or WAGs) in the workplace. Although results of some epidemiological studies suggest a link between exposure to halogenated anesthetics and increased health problems (particularly <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>), the relationship is not conclusive. Since exposure to WAGs is one possible factor in the findings for these studies, operating room personnel, and pregnant women in particular, should minimize exposure. Precautions include adequate general ventilation in the operating room, the use of a well-designed and well-maintained scavenging system; work practices to minimize leaks and spills while the anesthetic agent is in use, and routine equipment maintenance to minimize leaks.</span></span></span></p>
<p><span><span><span>Consistent with clinical data, concentrations would need to reach 2-3% in inspired air before individuals would likely experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or other physiologic effects.</span></span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L2dd6f410-627b-4e6c-9e1e-e6d975274e99"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at room temperature, 15°-30°C (59°-86°F). SUPRANE (desflurane, USP) has been demonstrated to be stable for the period defined by the expiration dating on the label. The bottle should be recapped after each use of SUPRANE (desflurane, USP).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L46d458b5-b11b-4bf0-9e65-3c6afd7ce4ff"></a><a name="section-15"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<p class="First">Anesthesia providers need to obtain the following information from patients prior to administration of anesthesia:</p>
<ul>
<li>Medications they are taking, including herbal supplements</li>
<li>Drug allergies, including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to anesthetic agents (including hepatic sensitivity)</li>
<li>Any history of severe reactions to prior administration of anesthetic</li>
<li>If the patient or a member of the patient's family has a history of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> or if the patient has a history of <span class="product-label-link" type="condition" conceptid="4296473" conceptname="Duchenne muscular dystrophy">Duchenne muscular dystrophy</span> or other latent neuromuscular disease</li>
</ul>
<p>Anesthesia providers should inform patients of the risks associated with SUPRANE (desflurane, USP):</p>
<ul>
<li>Post-operative <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and respiratory adverse effects including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>.</li>
<li>There is no information of the effects of SUPRANE (desflurane, USP) following anesthesia on the ability to operate an automobile or other heavy machinery. However, patients should be advised that the ability to perform such tasks may be impaired after receiving anesthetic agents.</li>
</ul>
<p>**************************************************************************************************************</p>
<p>Baxter and Suprane are trademarks of Baxter International Inc.</p>
<p><span class="Bold">Baxter</span></p>
<p>Manufactured for</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Deerfield, IL 60015 USA</p>
<p>**************************************************************************************************************</p>
<p>Revised 06/2012</p>
<p>MLT-00070/13.0                                                                                                                                                                              07-19-69-651</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L758ea636-5e9b-4aea-bd03-d1cdf08f42bf"></a><a name="section-16"></a><p></p>
<h1>SAMPLE PACKAGE LABELS</h1>
<p class="First"><img alt="Label1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Label1.jpg"><img alt="Label2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf4d8d29-852d-4281-b732-4af0eca019e1&amp;name=Label2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUPRANE 		
					</strong><br><span class="contentTableReg">desflurane liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52584-641(NDC:10019-641)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Desflurane</strong> (Desflurane) </td>
<td class="formItem">Desflurane</td>
<td class="formItem">240 mL  in 240 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52584-641-24</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">240 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52584-641-64</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">240 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020118</td>
<td class="formItem">04/25/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>General Injectables &amp; Vaccines, Inc
							(108250663)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>43b701ca-1121-43f6-807a-28c06f01fd88</div>
<div>Set id: bf4d8d29-852d-4281-b732-4af0eca019e1</div>
<div>Version: 4</div>
<div>Effective Time: 20130530</div>
</div>
</div> <div class="DistributorName">General Injectables &amp; Vaccines, Inc</div></p>
</body></html>
